ADMA Biologics, Inc.
NASDAQADMA heads into its August 7 earnings print with short sellers quietly reducing exposure even as the stock trades at a steep discount to analyst targets. Short interest is the primary tension here. At roughly 10% of the free float — about 23.8 million shares — ADMA carries a meaningful short position. Yet that figure has fallen around 1.8% over the past week and eased back after a…
Snapshot as of 24 Aug 2026
ADMA heads into its August 7 earnings print with short sellers quietly reducing exposure even as the stock trades at a steep discount to analyst targets. Short interest is the primary tension here. At roughly 10% of…
ADMA Biologics reports Q1 results on May 8 with short sellers quietly rebuilding positions after a sharp pullback — making the earnings print a test of whether the stock's recent momentum can hold. Short interest has…
ADMA Biologics reports Thursday with a familiar tension: a stock that has rallied 11.5% over the past month is now pulling back into the number, down 6% on the week to $10.25, while short interest has quietly rebuilt…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for ADMA — free to start on ORTEX.
Sign up for free →Open ADMA on ORTEX